The 36-month beta value for RVNC is also noteworthy at 0.84. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 1 rating it as “overweight,” 8 rating it as “hold,” and 0 rating it as “sell.”
The public float for RVNC is 95.70M, and at present, short sellers hold a 10.45% of that float. The average trading volume of RVNC on November 26, 2024 was 3.06M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
RVNC) stock’s latest price update
Revance Therapeutics Inc (NASDAQ: RVNC)’s stock price has plunge by 9.08relation to previous closing price of 3.80. Nevertheless, the company has seen a 10.24% surge in its stock price over the last five trading sessions. accesswire.com reported 2024-11-11 that NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. (“Revance Therapeutics, Inc.”) (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it “received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company’s exclusive distribution agreement with Teoxane SA”.
RVNC’s Market Performance
RVNC’s stock has risen by 10.24% in the past week, with a monthly drop of -29.75% and a quarterly drop of -37.01%. The volatility ratio for the week is 5.74% while the volatility levels for the last 30 days are 6.89% for Revance Therapeutics Inc The simple moving average for the last 20 days is -9.82% for RVNC stock, with a simple moving average of -9.44% for the last 200 days.
Analysts’ Opinion of RVNC
Many brokerage firms have already submitted their reports for RVNC stocks, with Mizuho repeating the rating for RVNC by listing it as a “Neutral.” The predicted price for RVNC in the upcoming period, according to Mizuho is $9 based on the research report published on January 29, 2024 of the current year 2024.
Goldman, on the other hand, stated in their research note that they expect to see RVNC reach a price target of $8, previously predicting the price at $30. The rating they have provided for RVNC stocks is “Neutral” according to the report published on January 09th, 2024.
Exane BNP Paribas gave a rating of “Neutral” to RVNC, setting the target price at $20 in the report published on August 16th of the previous year.
RVNC Trading at -17.96% from the 50-Day Moving Average
After a stumble in the market that brought RVNC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.47% of loss for the given period.
Volatility was left at 6.89%, however, over the last 30 days, the volatility rate increased by 5.74%, as shares sank -30.12% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.76% lower at present.
During the last 5 trading sessions, RVNC rose by +9.84%, which changed the moving average for the period of 200-days by -28.42% in comparison to the 20-day moving average, which settled at $4.60. In addition, Revance Therapeutics Inc saw -52.84% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RVNC starting from Hollander David, who sale 3,908 shares at the price of $4.17 back on Nov 18 ’24. After this action, Hollander David now owns 104,945 shares of Revance Therapeutics Inc, valued at $16,296 using the latest closing price.
Jordan Erica, the Chief Commercial Officer of Revance Therapeutics Inc, sale 2,392 shares at $3.80 during a trade that took place back on Apr 16 ’24, which means that Jordan Erica is holding 114,864 shares at $9,096 based on the most recent closing price.
Stock Fundamentals for RVNC
Current profitability levels for the company are sitting at:
- -0.67 for the present operating margin
- 0.71 for the gross margin
The net margin for Revance Therapeutics Inc stands at -0.73. The total capital return value is set at -0.44. Equity return is now at value -2096.78, with -36.38 for asset returns.
Based on Revance Therapeutics Inc (RVNC), the company’s capital structure generated 1.61 points at debt to capital in total, while cash flow to debt ratio is standing at -0.44. The debt to equity ratio resting at -2.64. The interest coverage ratio of the stock is -7.2.
Currently, EBITDA for the company is -290.64 million with net debt to EBITDA at -2.83. When we switch over and look at the enterprise to sales, we see a ratio of 3.47. The receivables turnover for the company is 5.12for trailing twelve months and the total asset turnover is 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.12.
Conclusion
In summary, Revance Therapeutics Inc (RVNC) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
